TCM
RYTM icon

Tekla Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Tekla Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-24,890
Closed -$548K – 196
2019
Q2 		$548K Hold
24,890
– – 0.02% 182
2019
Q1 		$682K Hold
24,890
– – 0.03% 174
2018
Q4 		$669K Hold
24,890
– – 0.03% 178
2018
Q3 		$726K Buy
+24,890
New +$787K 0.03% 189

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tekla Capital Management's RYTM Position: Q3 2019 in Review

Tekla Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2019, closing a stake of 24,890 shares — an estimated $548K sold.

Tekla Capital Management first reported a position in RYTM in Q3 2018 and held it in 4 quarters. The position peaked at $726K in Q3 2018. 84 funds tracked by Wall St. Rank hold RYTM as of Q3 2019.

  • Tekla Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Tekla Capital Management sold 24,890 Rhythm Pharmaceuticals shares in Q3 2019, an estimated $548K.
  • Tekla Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Tekla Capital Management's Rhythm Pharmaceuticals position peaked at $726K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.